Dr. Camilo de la Fuente-Sandoval transforms early psychosis care through neuroimaging breakthroughs Reports and Proceedings Genomic Press image: Camilo de la Fuente-Sandoval, MD, PhD, Instituto Nacional de Neurología y Neurocirugía, Mexico view moreCredit: Camilo de la Fuente-Sandoval, MD, PhD, Instituto Nacional de Neurología y Neurocirugía, Mexico MEXICO CITY, MEXICO, 29 July 2025 — In a […]
Peer-Reviewed Publication CNRS IMAGE: YOUNG LLAMA BORN NEAR THE BASE CAMP AT THE BEGINNING OF THE ICE MEMORY EXPEDITION IN BOLIVIA. view moreCREDIT: © BRUNO JOURDAIN / IGE / CNRS IMAGES While current treatments for schizophrenia — a mental illness affecting 1% of the world’s population — can reduce certain symptoms, they have little effect
Llama antibodies: New therapeutic avenues against schizophrenia Read More »
by Justin Jackson, Phys.org edited by Sadie Harley, reviewed by Andrew Zinin Copenhagen University Hospital’s VIRTU Research Group reports that an immersive virtual reality-assisted therapy called Challenge-VRT yielded a statistically significant, short-term reduction in auditory verbal hallucination severity among Danish adults with schizophrenia spectrum disorders. Auditory verbal hallucinations rank among the most frequent and distressing features of schizophrenia,
Virtual reality therapy reduces voice hallucinations in schizophrenia trial Read More »
Causes Genetics Environmental triggers Risk factors Diagnosis Contacting a doctor Summary Key takeaways Schizophrenia arises from a combination of genetic predisposition, early developmental factors, environmental influences, and biological processes, rather than a single cause. Environmental factors such as pregnancy complications, childhood trauma, substance use, and certain infections can increase the risk of schizophrenia in genetically
Schizophrenia causes: What to know Read More »
Bipolar disorder symptoms Schizophrenia symptoms Overlapping symptoms Substance use links Prevalence How experiences differ Diagnosis Treatment FAQ Summary Bipolar disorder and schizophrenia are mental health conditions that have some common traits and some key differences. Differences include the symptoms a person experiences. Bipolar disorder causes shifts in mood, energy level, and thinking. Schizophrenia causes a
Bipolar and schizophrenia: What are the similarities and differences? Read More »
A novel once-weekly capsule loaded with the antipsychotic risperidone, LYN-005, provided similar bioavailability and symptom control as daily doses of the drug in a phase 3 trial of patients with schizophrenia or schizoaffective disorder. The study was stopped early for success after an interim analysis showed all pharmacokinetic values met primary endpoint criteria. Weekly LYN-005
Weekly Pill Platform Succeeds in Schizophrenia, With Much Wider Promise Read More »
LOS ANGELES — The novel phosphodiesterase 10A (PDE10A) inhibitor known as CPL’36 (Celon Pharma) is effective and generally safe in acute exacerbations of schizophrenia, new research suggested. In a phase 2 trial of 189 patients with acute schizophrenia, compared with the placebo group, the groups receiving CPL’36 20 or 40 mg once daily both met
Novel PDE10A Inhibitor for Acute Schizophrenia Safe, Effective in Large Phase 2 Trial Read More »
Vitae, vulputate lorem id egestas neque egestas habitant sit ante nec.
✆ Phone (appointments): 714-639-4013
Email: care@imedmg.com
Address: 615 E Chapman Ave, Suite #300, Orange, CA 92866